Share on StockTwits

Analysts’ ratings reiterations for Monday, June 23rd:

Big Lots (NYSE:BIG) had its buy rating reissued by analysts at Deutsche Bank. Deutsche Bank currently has a $49.00 target price on the stock, up from their previous target price of $43.00.

A M Castle and (NYSE:CAS) had its buy rating reissued by analysts at Jefferies Group. Jefferies Group currently has a $16.00 price target on the stock, down from their previous price target of $17.00.

Continental Resources (NYSE:CLR) had its buy rating reiterated by analysts at Bank of America. The analysts wrote, “A week on the road with CLR in what was management’s first ever trip to Europe had one simple message: on multiple levels, risks to estimated total resource, production targets and ultimately cash flow appear skewed higher versus guidance that is almost two years old. Specifically, discussions with management centered on two issues: ongoing down spacing and upsize frac tests in the ND Bakken and the move to full development in the SCOOP. While management did not discuss specifics, confirmation of 3rd party analogs and critically, a subtle but steady increase in declared acreage in the SCOOP leads us to conclude management’s drilling backlog declared in October 2012 may no longer be reasonable.”

Coach (NYSE:COH) had its buy rating reaffirmed by analysts at Renaissance Capital. They currently have a $44.00 price target on the stock, down from their previous price target of $54.00.

CyrusOne (NASDAQ:CONE) had its overweight rating reaffirmed by analysts at Morgan Stanley. They currently have a $25.00 target price on the stock. The analysts wrote, “Cincinnati Bell’s (CBB) disposal of 36% (assuming 16m shares) of their stake in CyrusOne (CONE) clears the air, some five months after the IPO lock-up expired. For CBB, net leverage (2014E) drops from 5.9x at 1Q14 to 4.95x, with the opportunity to use the $356M plus wireless proceeds to restructure the balance sheet. Leverage net of the value of the remaining CONE stake, drops from 3.5x to 3.2x helped by the CONE stock price rally. For CONE, the public float jumps some 77% to 37M shares or about 56.3% of total shares outstanding, while CBB has committed to a 90-day lockup on its remaining shares.”

Darden Restaurants (NYSE:DRI) had its neutral rating reaffirmed by analysts at Susquehanna. Susquehanna currently has a $46.00 target price on the stock, down from their previous target price of $49.00.

Equity Residential (NYSE:EQR) had its neutral rating reaffirmed by analysts at Citigroup Inc.. The firm currently has a $66.00 price target on the stock, up from their previous price target of $57.00.

Embraer SA (NYSE:ERJ) had its buy rating reissued by analysts at Deutsche Bank. The firm currently has a $44.00 target price on the stock, up from their previous target price of $40.00.

Facebook (NASDAQ:FB) had its buy rating reissued by analysts at Sterne Agee. The firm currently has a $80.00 target price on the stock.

FMC Corp (NYSE:FMC) had its buy rating reiterated by analysts at Jefferies Group. The firm currently has a $85.00 price target on the stock, down from their previous price target of $88.00.

Galectin Therapeutics (NASDAQ:GALT) had its buy rating reiterated by analysts at Aegis.

Halliburton Company (NYSE:HAL) had its outperform rating reaffirmed by analysts at Credit Suisse. Credit Suisse currently has a $79.00 target price on the stock, up from their previous target price of $78.00.

HSN (NASDAQ:HSNI) had its buy rating reiterated by analysts at Citigroup Inc.. The firm currently has a $67.00 target price on the stock, up from their previous target price of $60.00.

International Flavors & Fragrances (NYSE:IFF) had its buy rating reiterated by analysts at Stifel Nicolaus. Stifel Nicolaus currently has a $110.00 target price on the stock, up from their previous target price of $103.00. The analysts wrote, “We hosted meetings with International Flavors & Fragrances CFO Kevin Berryman and IR head Shelley Young and offer the following takeaways. Overall, we continue to believe the company remains positioned to achieve 2014 sales, operating profit, and EPS growth above long-term targets driven by strong topline and operating momentum.”

Intersil Corp (NASDAQ:ISIL) had its buy rating reaffirmed by analysts at Stifel Nicolaus. They currently have a $19.00 target price on the stock, up from their previous target price of $16.00. The analysts wrote, “Near term, we believe the company is seeing solid demand across all of its three primary end markets, including computing, consumer and industrial & infrastructure. “We note that the company had guided for June quarter revenue to come in between $144-$150mn (or 5% q/q at the mid-point) and Non-GAAP EPS to come in between $0.17-$0.19 and while management has not updated its guidance, based on our current analysis of industry dynamics, we believe Intersil is likely tracking in-line or potentially above our current $147mn revenue and $0.18 Non-GAAP EPS estimates.”

Lazard (NYSE:LAZ) had its neutral rating reaffirmed by analysts at Citigroup Inc.. The firm currently has a $54.00 target price on the stock, up from their previous target price of $50.00.

LGI Homes (NASDAQ:LGIH) had its buy rating reiterated by analysts at Deutsche Bank. Deutsche Bank currently has a $20.00 price target on the stock, up from their previous price target of $18.00.

LifePoint Hospitals (NASDAQ:LPNT) had its buy rating reissued by analysts at Deutsche Bank. The firm currently has a $75.00 price target on the stock, up from their previous price target of $63.00.

Medivation (NASDAQ:MDVN) had its buy rating reiterated by analysts at Stifel Nicolaus. They currently have a $81.00 price target on the stock, down from their previous price target of $83.00. The analysts wrote, “Based on our survey of 40 doctors who treat prostate cancer, we believe that Xtandi has the potential to become the dominant pre-chemotherapy prostate cancer drug, ahead of Zytiga. “We base our belief on 3 factors: In their metastatic castrate resistant prostate cancer patients (mCRPC), urologists estimate 30% of their patients will start on Xtandi as their first systemic treatment, above 27% for Zytiga and 5% for chemotherapy. We believe that urologists will be the primary treating physicians in the front-line setting based on the high relative proportion of urologists writing Xtandi scripts prior to pre-chemo approval. Both urologists and oncologists said that overall survival benefit is the primary factor in choosing front-line therapy. “We note that in the Phase III PREVAIL trial, Xtandi had a 29% reduction of risk of death compared to 21% for Zytiga. Surveyed docs noted that they will use less chemotherapy in all lines of treatment, most notably the front-line. We believe that most of the patients who would have been treated with chemo will be treated with an oral anti-androgen instead and note that urologists preferred Xtandi to Zytiga by a 4-to-3 margin.”

Vail Resorts (NYSE:MTN) had its buy rating reiterated by analysts at Bank of America. Bank of America currently has a $92.00 target price on the stock, up from their previous target price of $80.00. The analysts wrote, “MTN remains one of our favorite ideas and is entering its typical summer/fall period of stock outperformance. We believe the story is changing and it is time to revisit MTN’s evolving business and growth opportunities: particularly its complicated but potentially lucrative lease and litigation in Park City, Utah. With FY14 almost complete, we are raising our price objective to $92 from $80, which is based on 12.0x our FY15E EBITDA (similar to its FY14 multiple), and reiterate our Buy rating.”

Nucor (NYSE:NUE) had its buy rating reiterated by analysts at Jefferies Group. The firm currently has a $58.00 target price on the stock.

ON Semiconductor Corp (NASDAQ:ONNN) had its buy rating reaffirmed by analysts at Morgan Stanley. The firm currently has a $11.00 price target on the stock, up from their previous price target of $10.00.

OSI Systems (NASDAQ:OSIS) had its buy rating reiterated by analysts at Benchmark Co.. They currently have a $78.00 target price on the stock.

Shire PLC (NASDAQ:SHPG) had its buy rating reiterated by analysts at CRT Capital. The firm currently has a $250.00 price target on the stock, up from their previous price target of $195.00.

Sirona Dental Systems (NASDAQ:SIRO) had its buy rating reissued by analysts at Jefferies Group. They currently have a $93.00 price target on the stock, up from their previous price target of $85.00.

Talisman Energy (NYSE:TLM) had its outperform rating reaffirmed by analysts at Bernstein. The firm currently has a $13.50 target price on the stock, down from their previous target price of $15.00.

Wynn Resorts, Limited (NASDAQ:WYNN) had its buy rating reiterated by analysts at Deutsche Bank. The firm currently has a $242.00 price target on the stock, down from their previous price target of $265.00.

XPO Logistics (NYSE:XPO) had its overweight rating reaffirmed by analysts at Morgan Stanley. They currently have a $32.00 target price on the stock. The analysts wrote, “XPO’s CEO Brad Jacobs has aggressive growth plans. If successful, XPO could be the single best performing stock in our universe through 2017. The stock is not without risk, but upside is compelling.”

Xylem (NYSE:XYL) had its neutral rating reissued by analysts at Citigroup Inc.. The firm currently has a $41.00 target price on the stock, up from their previous target price of $38.00.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.